FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026) HIMS: Regulatory Arbitrage and the Future of Personalized Medicine Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides BPC 157 & TB 500 Blend 10mg 10mg Peptide Tech Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law